WO2018199633A1 - Pharmaceutical composition for preventing or treating aging-related diseases containing decursin derivative as active ingredient - Google Patents

Abstract

The present invention relates to a novel decursin derivative and a composition for preventing or treating aging-related diseases containing the same as an active ingredient. The novel decursin derivative has exhibited an excellent effect of inhibiting progerin expression and an excellent effect of inhibiting binding between progerin and lamin A, and it has been confirmed that the novel decursin derivative prolongs the survival period of animal models in which progeria is induced. Therefore, a compound of the present invention can be effectively used for the prevention or treatment of aging-related diseases such as progeria, etc.

Description

A pharmaceutical composition for the prevention or treatment of aging-related diseases, which contains decusin derivative as an active ingredient.

The present invention relates to a novel decusin derivative and a composition for preventing or treating aging-related diseases containing the same as an active ingredient.

As the lifespan of humans increases, there is an increasing interest in the progression of aging, but there are still a number of areas that are not clear. Recent studies have focused on genetic or molecular aging mechanisms, mainly in human prematurity. have.

Premature ejaculation or Hutchinson Gilford progria syndrome (HGPS) is a fatal and rare genetic disorder that causes premature aging in young children.It is normal in early childhood, but it is usually about 9 to 24 months. This leads to serious growth delays, resulting in shorter and lesser weight. It has a characteristic face shape, systemic atherosclerosis, cardiovascular disease, stroke, hip dislocation, etc., loss of fat layer under the skin, nail defects, joint hardness, and skeletal damage. These patients with premature ejaculation usually die at ages 8-21 due to heart disease and have an average life expectancy of 13 years.

HGPS is a very rare autosomal dominant genetic disease caused by a silent mutation of G608G of Lamin A (LMN A). The mutation produces a new cleavage donor site and produces a selective cleavage site product, Progerin (Prg), in which the 50 amino acids of the C-terminal domain of Lamin A are deleted.

Expression of progerin leads to morphological changes such as nuclear membrane irregularity or reduction of nuclear-cytoplasmic lamin A. Inhibition of progerin leads to reduction of nuclear deformation, which has been identified as a major factor of HGPS.

Accordingly, there is a method of treating progenin by inhibiting farnesylation of progenin or by removing automated panesylated Lamin A by autophagy, but in both cases side effects problem There has been no report on the fundamental treatment of mania.

The present invention provides a novel compound that inhibits the binding of progerin and lamin A, and to provide a composition comprising the compound as an active ingredient as a pharmaceutical composition for preventing or treating aging-related diseases such as premature mania.

The present invention provides a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof.

[Formula 1]

The present invention provides a pharmaceutical composition for preventing or treating aging-related diseases containing a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.

[Formula 1]

In addition, the present invention provides a cosmetic composition for preventing or improving wrinkles comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof.

[Formula 1]

The novel compounds according to the present invention exhibited excellent progerin expression and inhibitory effect of progerin and lamin A binding in premature ejaculation-induced cells and animal models. In particular, oral administration resulted in progerin and lamin levels similar to intraperitoneal injection. As it has been shown to prolong the survival of the animal models in which the binding inhibitory effect of A and premature ejaculation have been induced, the compounds of the present invention are aging such as Hutchinson Gilford progria syndrome (HGPS) and Werner syndrome. It can be effectively used in the treatment of related diseases, the novel compounds of the present invention can be provided as a cosmetic composition for preventing or improving wrinkles as it has been found to increase collagen production of skin cells.

1 is a result of confirming the inhibitory effect of progerin-lamin A binding, Figure 1A in vivo PK analysis of JH4 confirmed the suppression of aging phenotype in progeria model mice injected with JH4 intraperitoneally, but very much when PO treatment Disappearing quickly is a confirmed result. Figure 1B is a schematic diagram showing the formation of JH4 derivatives, in order to suppress the rapid degradation in vivo, the side chain was replaced with amino bonds (JH010) or ether bonds (SLC-D011) to confirm the synthesized JH4 derivative compounds. FIG. 1C shows the effect of JH4 derivatives inhibiting Lamin A (LMNA) and progerin interactions. As a result, beads-bound LMNA transformed with GFP-progerin and each compound of 293 cell lysates Incubated together to perform binding inhibition assay. Figure 1D is a result of confirming the progerin expression inhibitory effect of SLC-D011 (D011) through progerin expression analysis, each compound was treated with progerin-transformed 293 cells 24 hours and confirmed progerin expression, JH4 Or D011 clearly shows an inhibitory effect on progerin expression compared to JH010. 1E shows the effect of D011 on improving nuclear morphology and inhibiting progerin expression, incubating the compound with HGPS cells (AG03198, 10-year-old female; AG03199; 10-year-old female) for 48 hours. After staining with progerin (red), the compounds improved abnormal morphology of the nucleus. In particular, it was confirmed that D011 had an excellent effect of improving, and DAPI means DNA. 1F is an immunostaining result confirming the effect of induction of H3K9me3 expression by JH010 and D011, H3K9me3 inhibition is a very well known marker in mania and immunostaining, all compounds showed the result of effectively dbehg H3K9me3 expression in HGPS cells .

FIG. 2 shows the significant in vivo effects of SLC-D011. FIG. 2A shows the in vivo PK analysis of JH010 and SLC-D011. Both compounds showed an appropriate PK profile, and BA showed bioavailability. ). Figure 2B is a result of confirming the human ERG (hERG) inhibitory effect of SLC-D011, as the hERG inhibitory effect is confirmed in JH010, as a result of confirming the effect of SLC-D011 on hERG, SLC-D011 shows hERG inhibitory effect Did. 2C shows the effect of SLC- ^D011 on prolonging lifespan of Lmna ^{G609G / G609G} , a progeria model mouse, compared with SLC-D011 20 compared with an average lifespan of 14.8 weeks (maximum lifespan 15 weeks). Intraperitoneal injection of mg / kg twice a week confirmed that life was extended to 19.5 weeks (up to 21 weeks), and SLC- ^D011 was injected into 5-week-old Lmna ^{G609G / G609G} mice. Figure 2D ^confirms the overall morphology of the 10-week-old Lmna ^{G609G / G609G} mice injected, it was confirmed that mice injected with SLC-D011 at the same age is larger than the control mice. FIG. 2E shows the effect of SLC- ^{D011 on} the lifespan of Lmna ^{wt / G609G} mice. SLC- ^D011 was ^compared with vehicle (ave = 44.6 and max = 46) and JH4 (ave = 54 and max = 56). The injected group was found to have an extended average lifespan of up to 65 weeks, with the injection starting at 43 weeks of age. FIG. 2F shows the entire form of Lmna ^{wt / G609G} mice injected with ^D011 , although weak and weak in 45-week-old Lmna ^{wt / G609G} mice, despite the same age as vehicle mice.

3 shows the effect of oral administration of SLC-D011 on premature aging. As a result of confirming solubility, FIG. 3A shows that SLC-D011 is very hydrophobic and thus does not dissolve in aqueous solution. On the left), in order to solve the above problem, the solubility was confirmed in the solution already used in the pharmaceutical formulation, and the solution based on the olein (monoolein) (right) was selected as the dissolution solution. 3B shows the stability of SLC-D011, which requires heating and sonication at 80 ° C. for complete dissolution, but SLC-D011 shows the same pattern as the original compound for heating and sonication as a result of LC-MS analysis. Not confirmed. Figure 3C shows the effect of extending the life of Lmna ^{G609G / G609G} mice by oral administration of SLC- ^D011 , 50 mg / kg daily orally administered SLC-D011 dissolved in olein solution to 5 week old mice The lifetime of the orally administered group was extended (ave = 19.3 and max = 19.5) compared to (ave = 14.9 and max = 15.5). Figure 3D confirms the increase in the weight of Lmna ^{G609G / G609G} mice following oral administration of SLC- ^{D011, it} was confirmed that the weight of the treated mice compared with the vehicle group was increased by 35%. Figure 3E is the result of confirming the overall shape of the 8-week-old SLC-D011 treated mice, the results confirmed that the body size of the treated mouse is larger than the vehicle-mouse.

4 is a result of confirming the improvement of premature aging of SLC-D011 in Werner syndrome cells, FIG. 4A shows that HGPS cells transformed with each vector for 48 hours were stained with H3K9me3 antibody and stained with H3K9me3 antibody. As a result of confirming the expression level, H3K9me3 expression was confirmed in HGPS cells transformed with human WRN (hWRN), while H3K9me3 expression was not observed in HGPS cells transformed with mouse WRN (mWRN). Figure 4B shows the human specific dual region involved in progerin-WRN binding, wherein the beads bound to GST WRN-R1 (non-repeatable peptide) and WRN-R2 (redundant peptide) were GFP-LmnA or progerin traits. Incubated with the injected 293 cell lysates and centrifuged to perform immunoplow assay, followed by Western blot analysis confirming the bound GFP protein. Figure 4C shows the effect of WRN-R2 inhibits the interaction of Lamin A with progerin, 293 lysate and GRN-Lamine A transformed bead-bound GST-progerin with WRN-R1 or R2 The incubation in the presence or absence of the present condition, it was confirmed that the amine A-progerin interaction was clearly reduced in the group to which the recombinant WRN-R2 is added. 4D shows the effect of recombinant WRN-R2 peptides inducing H3K9me3 and improving nuclear malformations after 24 hours of insertion of WRN-R1 and R2 peptides into HGPS cells using protein transport reagents. The H3K9me3 expression was increased in the cells and the nuclear shape was confirmed. 4E shows that H3K9me3 expression was induced by progerin removal in Werner syndrome (WS) patient cells. WS cells were transformed with si-control or si-progerin for 48 hours and H3K9me3. Staining with antibody and DAPI (nuclear staining) induced H3K9me3 expression and reduced nuclear size in WS cells expressing progerin by siRNA. Figure 4F is a result confirming the effect of the SLC-D011 to improve the nuclear malformation of WS cells, incubated for 48 hours WS cells and SLC-D011 and confirmed by staining with Lamin A / C antibody and DAPI. 4G shows the effect of induction of H3K9me3 expression by SLC-D011 in WS cells after 48 hours of incubation of SLC-D011 with WS cells, and the WS cells expressing very low H3K9me3 by SLC-D011 treatment. It was confirmed that H3K9me3 expression was clearly induced.

5 is a result of confirming the effect of SLC-D011 in human skin keratinocytes HaCaT cells and fibroblasts, Figure 5A was treated with SLC-D011 in HaCaT cells after incubation for 24 hours confirmed the amount of collagen 1A expression in HaCaT cells As a result of Western blot analysis, FIG. 5B shows collagen 1A after 24 hours incubation with SLC-D011 in normal fibroblasts 9N (GM 00038, 9-year-old female) and N46 (AG13299, 46-year-old male). Western blot analysis results confirmed the expression level.

The present invention can provide a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof.

[Formula 1]

The present invention can provide a pharmaceutical composition for preventing or treating aging-related diseases containing a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.

[Formula 1]

More specifically, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof is (7S)-(+)-8,8-dimethyl-7- (3-phenyl-allyloxy) -7,8-di Hydro-6H-pyrano [3,2-g] chromen-2-one {(7S)-(+)-8,8-Dimethyl-7- (3-phenyl-allyloxy) -7,8-dihydro- 6H-pyrano [3,2-g] chromen-2-one (SLC-D011)}.

The aging-related disease may be premature ejaculation.

In more detail, the premature ejaculation may be selected from the group consisting of Werner syndrome and Hutchinson Gilford syndrome.

The compound represented by Formula 1 and a pharmaceutically acceptable salt thereof may inhibit the binding between progerin and lamin A.

In one embodiment of the invention, the pharmaceutical composition is any one selected from the group consisting of injections, granules, powders, tablets, pills, capsules, suppositories, gels, suspensions, emulsions, drops or solutions according to conventional methods Formulations of

In another embodiment of the present invention, the pharmaceutical composition is a suitable carrier, excipient, disintegrant, sweetener, coating agent, swelling agent, lubricant, glidant, flavoring agent, antioxidant, buffer, bacteriostatic agent, which are commonly used in the preparation of pharmaceutical compositions, It may further comprise one or more additives selected from the group consisting of diluents, dispersants, surfactants, binders and lubricants.

Specifically, the carriers, excipients and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil can be used, and solid preparations for oral administration include tablets, pills, powders, granules, capsules. And the like, and such solid preparations may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin and the like in the composition. In addition to simple excipients, lubricants such as magnesium styrate and talc may also be used. Oral liquid preparations include suspensions, solvents, emulsions, syrups, and the like, and may include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. Witsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like may be used as the base material of the suppository.

According to one embodiment of the invention the pharmaceutical composition is intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, nasal, inhaled, topical, rectal, oral, intraocular or intradermal Via the route can be administered to the subject in a conventional manner.

The preferred dosage of the compound represented by Formula 1 may vary depending on the condition and weight of the subject, the type and extent of the disease, the drug form, the route of administration, and the duration, and may be appropriately selected by those skilled in the art. According to one embodiment of the present invention, but not limited thereto, the daily dosage may be 0.01 to 200 mg / kg, specifically 0.1 to 200 mg / kg, more specifically 0.1 to 100 mg / kg. Administration may be administered once a day or divided into several times, thereby not limiting the scope of the invention.

In the present invention, the 'subject' may be a mammal including a human, but is not limited thereto.

In addition, the present invention can provide a cosmetic composition for preventing or improving wrinkles comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof.

[Formula 1]

The compound represented by Chemical Formula 1 and its pharmaceutically acceptable salt may improve collagen production in keratinocytes and fibroblasts.

The cosmetic composition may include conventional auxiliaries such as stabilizers, solubilizers, vitamins, pigments and flavors, and a carrier, in addition to the compound represented by Formula 1 as an active ingredient.

The cosmetic composition may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, oils, powder foundations, emulsion foundations, It may be formulated as a wax foundation and spray, but is not limited thereto. More specifically, it may be prepared in the form of a sun cream, a flexible lotion, a convergent lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a pack, a spray or a powder.

When the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc or zinc oxide may be used as a carrier component. .

If the formulation is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray additionally chlorofluorohydrocarbon, propane / butane Or propellants such as dimethyl ether.

When the formulation is a solution or emulsion, a solvent, solubilizer or emulsion is used as carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 Fatty acid esters of butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.

When the formulation is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cellulose as carrier components , Aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

Hereinafter, examples will be described in detail to help understand the present invention. However, the following examples are merely to illustrate the content of the present invention is not limited to the scope of the present invention. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.

Reference Example Substances and Equipment

¹ H and ¹³ C NMR spectra were measured using a JNM-AL 400 spectrometer (400 MHz, JEOL, Japan), and the melting point was measured at the Electrotheramal melting point apparatus (Yamaco. MD-S3) for mass spectrometry. The instrument was performed using an API 2000 LC / MS / MS spectrometer (PE Sciex, Canada), respectively.

In addition, the optical rotations were measured on a JASCO DIP-360 automatic digital polarimeter, and the purity of the chiral material was measured by HPLC (Shimadzu LC-6AD, Japan), column (CHIRACEL OD-H 0.46 cmф x 25 cm, DAICEL). CHEMICAL IND., Co. Osaka, Japan).

Silica gel for the material separation was used SiliaFlash® P60 (SILICYCLE, 230 ~ 400mesh), thin film TLC plate was used TLC silica gel 60 F254 (MERCK).

Solvents and reagents used in the synthesis of materials were purchased from Sigma-Aldrich, Fluka, TCI, Junsei, Duksan pure chemical, SK Chemical and SAMCHUN chemical.

< Example  1> (+)-of ether-form Decker ( decursin ) Derivative Synthesis (SLC-D011)

(7S)-(+)-8,8-dimethyl-7- (3-phenyl-allyloxy) -7,8-dihydro-6H-pyrano [3,2- in the same manner as in Schemes 1 and 2 g] chromen-2-one {(7S)-(+)-8,8-Dimethyl-7- (3-phenyl-allyloxy) -7,8-dihydro-6H-pyrano [3,2-g] chromen -2-one; SLC-D011} was synthesized.

1. Synthesis Process Ⅰ

Scheme 1

Step (I): Dissolve trans-cinnamic acid (D011a, 5 g, 33.7 mmol) in methanol (50 ml) in a 100 ml round flask, add 5 drops of concentrated H ₂ SO ₄ , and add 80 The mixture was heated at reflux for 24 hours to reflux, and the reaction mixture was cooled to room temperature and then concentrated under reduced pressure.

Thereafter, the mixture was separated with dichloromethane (300 ml) and distilled water (300 ml), and the organic layers were collected, dehydrated with sodium sulfate, and filtered.

The filtrate obtained after filtration was concentrated under reduced pressure to obtain 3-phenyl-acrylic acid, methyl ester (D011b, 5.39 g, yield = 98.5%) as a pure product, which was applied to the next step.

Step (II): 3-phenyl-acrylic acid, methyl ester (D011b, 4g, 24.7mmol, 1eq) was added to a 500 ml round flask filled with N ₂ gas. After dissolving with (dichloromethane), it was installed in a low temperature reactor adjusted to -78 ℃.

Diisobutylalumminium hydride 1M solution (DIBAL-H; 1M solution in hexane, 74 ml, 74.0 mmol, 3 eq) was slowly added dropwise to the reaction solution over 30 minutes, and then the reaction temperature was adjusted to 0 ° C. Methanol (22 ml) was slowly added dropwise while stirring to raise for 1 hour.

The reaction solution was transferred to room temperature, stirred for 30 minutes, and a saturated aqueous solution of Rochelle's salt (88 ml) was added thereto.

The reaction mixture was stirred vigorously at room temperature for 2 hours, separated twice with dichloromethane (300 ml) and distilled water (300 ml), and the organic layers were collected and dehydrated with sodium sulfate. The filtrate was concentrated under reduced pressure.

The concentrate was purified via silica gel column separation (ethyl acetate: n-hexane = 3: 1) to give pure product 3-phenyl-pro-2-phen-1-ol (3-phenyl-pro-2-pen-1-ol; D011c , 3.1g, yield = 93.9%, Rf = 0.37 (2: 1 n-hexane-ethyl acetate) were obtained and applied to the next step.

Step (III): 3-phenyl-pro-2-phen-1-ol (3-phenyl-pro-2-pen-1-ol, D011c, 1 g, 7.45 mmol, 1 eq) in a 100 ml round flask The solution was dissolved in anhydrous dichloromethane, and PBr3 (phosphorous tribromide, 253.6 µl, 2.608 mmol, 0.35 eq) was added to the water-vaporization solution and stirred for 1 hour.

The reaction mixture was concentrated and purified through silica gel column separation (ethyl acetate: n-hexane = 1: 8) to pure product (3-bromo-propenyl) -benzene [(3-bromo-propenyl) -benzene, D005d, 1.42 g, yield = 96.2%, Rf = 0.34 (5: 1 n-hexane-ethyl acetate)] were obtained and applied to the next step.

Step (IV): Under N2 gas, (S)-(+)-decursinol (SLC-B001, 2.33 g, 9.47 mmol, 1 eq) was added to a 100 ml round flask with anhydrous N, N-dimethylform. It was dissolved in amide (N, N-dimethylformamide, DMF; 10 ml) and installed in a low temperature reactor set to -20 ℃.

To the reaction mixture, (3-bromo-propenyl) -benzene [(3-bromo-propenyl) -benzene, D005d, 2.8 g, 14.2 mmol, 1.5 eq] and sodium sulfate (NaH 60%, 757 mg, 18.9 mmol, 2 eq) was added and stirred for 4 hours, 3 ml of distilled water was added, and after 10 minutes, taken out of the low temperature reactor, the solution was separated twice with 200 ml of dichloromethane and 200 ml of distilled water. Concentrated under reduced pressure.

The concentrate was separated by silica gel column separation (ethyl acetate: n-hexane = gradient elution to 1: 3 from 1:10) to give (7S)-(+)-8,8-dimethyl-7- (3-phenyl-allyloxy)- 7,8-dihydro-6H-pyrano [3,2-g] chromen-2-one {(7S)-(+)-8,8-Dimethyl-7- (3-phenyl-allyloxy) -7 , 8-dihydro-6H-pyrano [3,2-g] chromen-2-one (SLC-D011)} 1.21 g, (35.3%); Yield 35.3%, white solid, mp: 143 ° C., R _f = 0.39 (2: 1 n-hexane-ethyl acetate); [α] ²⁵ _D + 117.6 (c = 1, CHCl ₃ ); ¹ H NMR (400 MHz, CDCl ₃ ): δ _H 7.56 (1H, d, J = 9.6 Hz, H-4), 7.38-7.23 (5H, m, H-5 ′, H-6 ′, H-7 ′ , H-8 ', H-9'), 7.15 (1H, s, H-5), 6.76 (1H, s, H-10), 6.59 (1H, d, J = 16.0 Hz, H-3 ') , 6.30-6.23 (1H, m, H-2 '), 6.20 (1H, d, J = 9.6 Hz, H-3), 4.34 (1H, dd, J = 6.0, 12.8 Hz, H-1a'), 4.21 (1H, dd, J = 6.0, 12.4 Hz, H-1b '), 3.59 (1H, dd, J = 5.2, 7.6 Hz, H-7), 3.07 (1H, dd, J = 4.8, 16.0 Hz, H-6a), 2.85 (1H , dd, J = 7.2, 16.4Hz, H-6b), 1.41 (3H, s CH 3 -8), 1.36 (3H, s, CH 3- 8); ¹³ C NMR (100 MHz, acetone-d ₆ ) δ _C 161.2 (C-2), 157.8 (C-9a), 155.3 (C-10a), 144.5 (C-4), 137.9 (C-4 '), 132.9 (C-3 '), 130.4 (C-5), 129.6 (C-6', C-8 '), 128.6 (C-7'), 127.5 (C-2 '), 127.4 (C-5' , C-9 '), 118.3 (C-5a), 113.7 (C-3), 113.6 (C-4a), 104.5 (C-10), 78.8 (C-7), 76.4 (C-8), 70.8 (C-1 '), 27.8 (C-6), 26.1 (CH 3 -8), 22.2 (CH 3 -8); ESI-MS: m / z = 363 [M + H] ⁺ . Anal. Calc. for C ₂₃ H ₂₂ O ₄ : C, 76.22; H, 6. 12; Found: C, 76.20; H, 6.10.

2. Synthesis Process Ⅱ

Scheme 2

Step (I): Dissolve trans-cinnamic acid (D011a, 5g, 33.7mmol) in 50 ml of methanol in a 100 ml round flask, add 5 drops of concentrated H ₂ SO _4, and then at 80 ° C for 24 hours. Heated to reflux. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, separated into dichloromethane (300 ml) and distilled water (300 ml), an organic layer was collected, dehydrated with sodium sulfate, and filtered.

Filtrate was concentrated under reduced pressure after filtration to obtain 3-phenyl-acrylic acid, methyl ester (3-phenyl-acrylic acid, methyl ester, D011b, 5.39 g, yield = 98.5%), which was applied to the next step. It was.

Step (II): 3-phenyl-acrylic acid, methyl ester (D011b, 4g, 24.7mmol, 1eq) was added to a 500 ml round flask filled with N ₂ gas, dissolved in anhydrous dichloromethane, and then cooled to -78 ° C. Installed in a low temperature reactor fitted.

Diisobutylaluminum hydride 1M solution (DIBAL-H; 1M solution in hexane, 74 ml, 74.0 mmol, 3 eq) was slowly added dropwise to the reaction solution over 30 minutes, and then the reaction temperature was increased to 0 ° C. for 1 hour. Methanol (22 ml) was slowly added dropwise with stirring.

The reaction solution was transferred to room temperature, stirred for 30 minutes, and a saturated aqueous solution of Rochelle's salt (88 ml) was added thereto. The reaction mixture was stirred vigorously for 2 hours at room temperature, and partitioned twice with dichloromethane (300 ml) and distilled water (300 ml).

The organic layer was collected, dehydrated with sodium sulfate, filtered and the filtrate was concentrated under reduced pressure.

The concentrate was purified by silica gel column separation (ethyl acetate: n-hexane = 3: 1) to obtain pure product 3-phenyl-pro-2-phen-1-ol (3-phenyl-pro-2-pen-1-ol, D011c, 3.1 g, yield = 93.9%, Rf = 0.37 (2: 1 n-hexane-ethyl acetate) were obtained and the compound was applied to the next step.

Step (III): 3-phenyl-pro-2-phen-1-ol (D011c, 1 g, 7.45 mmol, 1 eq) was added to a 100 ml round flask filled with N ₂ gas, and dissolved in anhydrous dichloromethane. Trimethylamine (Et3N, 1.04 ml, 7.45 mmol, 1 eq), 4-dimethylaminopyridine (4-dimethylaminopyridine, 4-DMAP, 92 mg, 0.75 mmol, 0.1 eq), di-talt-butyl-dicarbonate (di- tert-butyl-dicarbonate, Boc 2 O, 2.57 ml, 11.18 mmol, 1.5 eq) was added sequentially, and the reaction solution was stirred at room temperature for 2 hours.

After concentrating the reaction mixture, silica gel column separation (ethyl acetate: n-hexane = 1: 30) was performed to obtain pure product tert-butyl cinnamyl carbonate (D011d, 1.30 g, yield = 74.7%). R _f = 0.32 (20: 1 n-hexane-ethyl acetate) was obtained and the compound was subjected to the next step.

Step (IV): Turt-butyl cinnamil carbonate (D011d, 1.43 g, 6.09 mmol, 1.5 eq), (S)-(+)-decursinol (SLC-B001, 1 g, in a 100 ml round flask 4.06 mmol, 1 eq) was added and dried in a vacuum for 1 hour.

The dried mixture under N ₂ gas dry tetrahydrofuran (tetrahydrofuran) as dissolved, using the N ₂ gas and then the solution for 1 hour bubbled (bubbling), tetra the reaction mixture tetrakis (triphenylphosphine) Palladium (Pd (PPh ₃ ) ₄ , 188 mg, 0.162 mmol, 0.04 eq) was added and then refluxed overnight. The mixture was concentrated under reduced pressure, followed by silica gel column separation (ethyl acetate: n-hexane = gradient elution to 1: 4 from 1: 8) to compound (7S)-(+)-8,8-dimethyl-7- ( 3-phenyl-allyloxy) -7,8-dihydro-6H-pyrano [3,2-g] chromen-2-one {(7S)-(+)-8,8-Dimethyl-7- ( 1.20 g (81.3%) of 3-phenyl-allyloxy) -7,8-dihydro-6H-pyrano [3,2-g] chromen-2-one (SLC-D011)} was obtained.

Yield 81.3%, white solid, mp: 143 ° C., R _f = 0.39 (2: 1 n-hexane-ethyl acetate); [α] ²⁵ _D + 117.6 (c = 1, CHCl ₃ ); ¹ H NMR (400 MHz, CDCl ₃ ): δ _H 7.56 (1H, d, J = 9.6 Hz, H-4), 7.38-7.23 (5H, m, H-5 ', H-6', H-7 ', H-8', H-9 '), 7.15 (1H, s, H-5), 6.76 (1H, s, H-10), 6.59 (1H, d, J = 16.0 Hz, H-3 '), 6.30-6.23 (1H, m, H-2 '), 6.20 (1H, d, J = 9.6 Hz, H-3), 4.34 (1H, dd, J = 6.0, 12.8 Hz, H-1a'), 4.21 (1H, dd, J = 6.0, 12.4 Hz , H-1b '), 3.59 (1H, dd, J = 5.2, 7.6 Hz, H-7), 3.07 (1H, dd, J = 4.8, 16.0 Hz, H-6a), 2.85 (1H, dd, J = 7.2, 16.4Hz, H-6b ), 1.41 (3H, s CH 3 -8), 1.36 (3H, s, CH 3 -8); ¹³ C NMR (100 MHz, acetone-d ₆ ) δ _C 161.2 (C-2), 157.8 (C-9a), 155.3 (C-10a), 144.5 (C-4), 137.9 (C-4 '), 132.9 (C-3 '), 130.4 (C-5), 129.6 (C-6', C-8 '), 128.6 (C-7'), 127.5 (C-2 '), 127.4 (C-5' , C-9 '), 118.3 (C-5a), 113.7 (C-3), 113.6 (C-4a), 104.5 (C-10), 78.8 (C-7), 76.4 (C-8), 70.8 (C-1 '), 27.8 (C-6), 26.1 (CH 3 -8), 22.2 (CH 3 -8); ESI-MS: m / z = 363 [M + H] ⁺ . Anal. Calc. for C ₂₃ H ₂₂ O ₄ : C, 76.22; H, 6. 12; Found: C, 76.20; H, 6.10.

Example 2 Confirmation of Effect of SLC-D011 as Lamin A (LMN A) -Progerin Binding Inhibitor

1. Animal Experiment

Animal testing was conducted by the Institute for Accreditation Evaluation and Laboratory Animal Care Certification Body, in accordance with the animal policy approved by Pusan National University.

Lmna ^{G609G / 609G} mice were generated through the proper mating of the heterozygous Lmna ^{+ / G609G} provided by Carlos Lopez-Otin (Universidad de Oviedo, Asturias, Oviedo, Spain).

SLC-D011 20 mg / kg mixed with DMOS and PBS was injected intraperitoneally twice a week in 5 week old mice. In addition, SLC-D011 dissolved in a concentration of 10 mg / ml in an olein-based solution was orally administered to the mice five times a week, control mice were administered only olein-based solution under the same conditions.

Lmna ^{G609G / 609G} mice started dosing at 5 weeks of age and were treated with fresh compound solution throughout their lifetime. Lmna ^{+ / G609G} mice started intraperitoneal treatment at 32 weeks of age.

2. Cell Culture and Reagents

HGPS patients (AG03198, 10-year-old female; AG03199; 10-year-old female), WS patients (AG06300, 37-year-old male; AG03141, 30-year-old female; AG00780, 60-year-old male) and control (GM 00038, 9-year-old female) human fibroblasts obtained from Coriell Cell Repositories (Camden, New Jersey, USA), EMEM medium or antibiotic containing 15% FBS, 2 mM glutamine And maintained in HEMEM containing 26 mM HEPES.

HEK293 cell lines were obtained from ATCC and maintained at 37 ° C. using DMEM liquid medium containing 10% FBS and 1% antibiotic.

3. Antibodies and Reagents

GFP (Full name; 1: 1000; sc-9996; Santa Cruz Biotechnology); Glutathione S-transferase (GST; 1: 5000; sc-138; Santa Cruz Biotechnology); Actin (1: 10000; sc-47778; Santa Cruz Biotechnology); Lamin A / C; 1: 10000; sc-376248; Santa Cruz Biotechnology); Progerin (Progerin; 1: 300; sc-81611; Santa Cruz Biotechnology); Progerin (1: 300; ab66587; Abcam); Antibodies such as H3K9me3 (1; 2000; Ab8898; Abcam) were used for the experiment.

4. Recombinant Protein

To produce recombinant protein, cloning of 100 AA from upstream of the stop codon via PCR produced recombinant Lamin A C-terminal region (Lamin A-C) and Progerin C-terminal region (Progerin C).

The WRN-R1 region (hWRN 424-450) and WRN-R2 region (hWRN 424-476) were produced in a similar manner. Each fragment was loaded into GSH-agarose, washed extensively and eluted using a buffer containing 20 mM reduced glutathione.

The eluted fragments were further purified using anion exchange chromatography (HitrapQ) to obtain the WRN-R1 and WRN-R2 amino acid sequences as follows.

WRN-R1: HLSPNDNENDTSYVIESDEDELEMEMLK

WRN-R2: HLSPNDNENDTSYVIESDEDELEMEMLK HLSPNDNENDTSYVIESDEDELEMEMLK

5. Western Blot Analysis

Whole cell lysates were prepared using RIPA.

15 μg cell extracts were separated on SDS-PAGE and transferred onto PVDF membrane.

The membrane was incubated with the primary antibody for 1 hour to overnight at 4 ° C. and then reacted for 1 hour at room temperature with the secondary antibody.

Peroxidase activity was confirmed by chemiluminescence according to the manufacturer's instructions using the ECL kit (Intron, Seoul, Korea).

6. Protein-protein interaction analysis

To analyze protein-protein interactions, glutathione S-transferase (GST) immune pull-down assays were performed.

To detect the interaction, the GST-based fusion lamin AC-terminal region, progerin-C-terminal region, WRN-R1 region or WRN-R2 region was GFP tagged progerin (GFP-Progerin) and lamin A (GFP). Incubated with HEK293 cell lysates transfected with -Lamin A) at room temperature for 30 minutes.

Then washed once with PBS, the precipitated material was collected and separated on SDS-PAGE followed by Western blot with anti-GFP and GST.

To confirm the competition of WRN-R1 and R2 for progerin and lamin A binding, beads with GST-progerin bound to GFP-Lamine A in the presence or absence of WRN-R1 or R2 recombinant protein Incubation with 293 lysates overexpressed.

7. Immunofluorescence staining and staining of β-galactosidase activity of aging specific acid

Cells were seeded onto cover glass and transfected with the appropriate vector.

Cells were incubated with blocking buffer (PBS + anti-human-Ab; 1: 400) after fixing for 1 hour at 4 ° C. with 100% methanol or 1% paraformaldehyde (PFA).

After washing twice with PBS, anti-lamin A / C, progerin or H3K9Me3 is diluted 1: 200 in blocking buffer to incubate with cells overnight and subsequently anti-goat Ab-FITC or anti-rabbit Ab- Blocking buffer containing rhodamine (1: 500) was incubated for 7 hours and nuclei stained with DAPI. Thereafter, immunofluorescence signals were detected using fluorescence microscopy (Zeiss and Logos).

For age specific acid-β-galactosidase activity staining, cells were washed once with PBS (pH 7.2) and fixed with PBS with 0.5% glutaraldehyde.

It was then washed with PBS and cells were stained overnight at 37 ° C. with X-gal solution.

8. Plasma Transfection and Protein Transport

GFP-progerin and GFP-fusion lamin A expression vectors were provided by T. Misteli (National Cancer Institute [NCI], Bethesda, Maryland, USA), and Myc-human WRN vectors and Myc-mouse WRN vectors were purchased from Addgene. .

Transfection was performed using jetPEI (Polyplus Transfection) and PULSin (Polyplus Transfection, New York, USA) according to the manufacturer's instructions.

To deliver the WRN-R1 and R2 proteins into HGPS cells, PULSin (Polyplus Transfection, New York, USA) was used according to the manufacturer's instructions.

After diluting the recombinant protein (2 μg) with 200 μl 20 mM Hepes, PULSin reagent (8 μl) was added. The mixture was incubated at room temperature for 15 minutes before cells were added. After 3 hours the serum free medium was replaced with medium containing 10% FBS and incubated for 4 hours. The mixture containing medium was then removed from the wells and filled with fresh medium containing serum.

9. Cell count

To count cells with malformed nuclei, the obtained immunofluorescence images were used. Nuclear membranes that appear to be laminally A stained dependently deformed are counted in randomly selected zones and the counted cells are expressed as percentages.

To measure cell proliferation, DAPI stained cells were counted in immunofluorescence images.

10. Compound pharmacokinetic (PK) analysis and in vitro ADME confirmation

For pharmacokinetic (PK) analysis, 10% DMSO, 5% Tween 90 and 95% physiological saline solution dissolved in 5 mg / kg of JH4 were injected intraperitoneally, and 10% NMP and 90% PEG400 solution in 10 mg / kg of JH4 dissolved. Oral administration. At defined times, blood concentrations of JH4 were analyzed by LC-MS / MS, and other compounds were analyzed by PK in the same procedure.

In vitro ADME studies (plasma protein binding, CYP inhibition, microsomal stability, plasma stability and hERG inhibition) were performed at new drug development centers by standard methods.

11. Confirmation of SLC-D011 Effect as a Progerin-Lamine A Binding Inhibitor

Hutchinson Gilford's syndrome is a well-known progerin syndrome, a rare genetic disorder. Genetic causes include a single point mutation in Lamin A resulting in abnormal donor conjugation, resulting in progerin with the C-terminal 50 amino acid deleted therein.

In a previous report, the inventors of the present invention confirmed that the nuclear malformation of HGPS cells was due to a very strong binding between Lamin A and progerin, and the progerin inhibitor (JH4) from Lamin A binding improved nuclear deformation of HGPS cells. Aging related markers such as, p16 / INK4A, DNA-PK, and H3K9me3 expression were restored. In addition, JH4 treatment via intraperitoneal injection (i.p) prolonged the lifespan of progerin model mice for about 4 weeks.

However, considering the patient's condition, HGPS patients had a very thin blood vessel wall, and intravenous injection was not an appropriate delivery method, confirming the possibility of oral administration of JH4.

As a result, JH4 injected intravenously and orally administered as shown in Figure 1A, Table 1 and Table 2 showed a very short half-life in vivo, and thus could not confirm the availability in vivo (B.A).

Accordingly, in order to obtain a stable compound in vivo, various compounds were modified from JH4, and GST-pull down assay and progerin expression analysis were performed to identify 41 different kinds of JH4 derivatives. As shown in 1C, JH010 and SLC-D011 compounds exhibited similar activities to JH4, and as shown in FIG. 1D, it was confirmed to exhibit an effect of inhibiting progerin expression.

1E and 1F, JH010 and SLC-D011 compounds induced H3K9me3 expression and improved nuclear malformation of HGPS cells.

In the results of the PK analysis, JH010 and SLC-D011 (progerinin), as shown in FIG. 2A, improved the bioavailability (B.A) by 70% and 66%, respectively.

However, in vitro ADME analysis confirmed that hERG ion channel inhibition in the JH010 compound, as a result of confirming the effect of SLC-D011 on the hERG ion channel, SLC-D011 showed a significant hERG inhibition compared to JH010 as shown in Figure 2b As shown in Tables 3 to 6, it was confirmed that the SLC-D011 compound exhibited good plasma stability and an appropriate range of CYP inhibition.

In order to confirm the in vivo effect of SLC-D011 confirmed the stability as described above, as a result of ip injection, the life of the Lamn ^{G609G / G609G} mouse as shown in Figure 2C has been extended to 20 weeks, as shown in Figure 2D SLC-D011 Treatment also improved body size and gross morphology.

Of particular interest is the extended lifespan of mice from 45 to 64 weeks by SLC- ^D011 treatment in the Lamn ^{wt / G609G} model, which is a much improved result compared to JH4 which extended the life span of about 10 weeks with reference to FIG. 2E. In addition, as shown in Figure 2F it was confirmed that the shape of the hair condition and body size of the mouse treated SLC-D011 is very improved.

From the above results, SLC-D011 can be proposed as a very good candidate for HGPS.

12. Confirmation of SLC-D011 oral administration effect

SLC-D011 as well as JH4 showed very low water solubility, and since such low water solubility is a problem for compound delivery through oral administration, a suitable solution can be screened to increase the SLC-D011 dissolution rate.

As a result, it can be seen that the solution based on olein (monoolein) is useful for dissolving SLC-D011, as shown in Figure 3A, SLC-D011 in the solution as shown in Figure 3B was confirmed that it is not decomposed and stable even under heating and ultrasonic treatment Could.

Olein-based solutions are also well suited as SLC-D011 carriers because they can increase intestinal absorption without toxicity.

SLC-D011 prepared in oral dosage form dissolved in an oleine-based solution was orally administered to Lamn ^{G609G / G609G} mice to confirm the in vivo effect. As shown in FIGS. 3C and 3D, the lifespan of Lamn ^{G609G / G609G} mice was increased. Extended to 4.5 weeks, weight gain was noted.

From these results, Olein-based SLC-D011 solution was found to be very useful for HGPS treatment.

Example 3 Confirmation of SLC-D011 Effect as a Werner Syndrome Therapeutic Agent

Since progerin expression is increased by aging, the effect of SLC-D011 has been confirmed in other premature diseases such as Werner syndrome (WS) and normal aging models.

First, the association between the lack of WRN gene and progeria was confirmed. According to the previous report, the body weight and lifespan of the WRN-induced mice were not clearly different from those of the wild-type mice, and the lifespan and body weight of the mWRN ^{− / −} mice were also different from those of the Lamn ^{wt / G609G} mice. It was confirmed that it was not shown.

In addition, when comparing the amino acid sequence of the mouse and human WRN, it was confirmed that the specifically repeated sequence (WRN-R2) in the human WRN, the duplication of hWRN actually occurred due to the repeated cDNA.

To investigate the relationship between hWRN and progerin, human and mouse WRN were transfected into HGPS cells and confirmed nuclear morphology and H3K9me3 expression.

As a result, interestingly, nuclear modification was improved only in hWRN as shown in FIG. 4A, and H3K9me3 expression was induced. In addition, recombinant peptides were made from single and double repeated amino acids and confirmed interactions with progerin.

As a result of comparison with WRN-R1, as shown in FIG. 4B, the double peptide was strongly bound to progerin, and as shown in FIG. 4C, WRN-R2 blocked progerin and lamin A interaction.

As a result, it was confirmed that WRN-R2 was a natural progerin inhibitor. As a result, the recombinant WRN-R2 was treated with HGPS cells and WS cells. As shown in FIG. Was normalized, and H3K9me3 expression was confirmed to be improved.

However, as it was confirmed that the same effect was observed in WS cells depleted of progerin, to confirm whether SLC-D011 can be used as a therapeutic agent suitable for treating WS cells, after treatment with SLC-D011 on WS cells, the nucleus was treated. Morphology and cell proliferation were confirmed.

As a result, as shown in FIG. 4F, SLC-D011 improved nuclear morphology and cell proliferation similar to HGPS in cells of WS patients, and induced expression of H3K9me3 as in 4G.

From the above results, it was confirmed that SLC-D011 can be used to treat Werner's syndrome, which is an adult prematurity.

Example 4 Confirmation of Skin Aging Improvement Effect of SLC-D011 Compound

In the previous experiments, as the SLC-D011 compound was found to have a therapeutic effect on aging-related diseases, the effect of the compound on the human skin keratinocytes, HaCaT cells and fibroblasts, was confirmed.

Human skin keratinocytes were incubated with HaCaT cells and normal fibroblasts 9N (GM 00038, 9-year-old female) and N46 (AG13299, 46-year-old male) treated with 2 or 5 μM SLC-D011 for 24 hours. Afterwards, collagen 1A expression levels were confirmed in HaCaT cells and fibroblasts.

As a result, as shown in Figures 5A and 5B SLC-D011 was confirmed to exhibit an effect of increasing the collagen expression in human fibroblasts and keratinocytes.

From the above results, it was confirmed that the SLC-D011 compound is suitable as a progerin-lamin A binding inhibitor, and the SLC-D011 compound may be provided for oral administration, so that it may be used as an effective anti-corrosive agent or a composition for improving wrinkles.

Having described the specific part of the present invention in detail, it is obvious to those skilled in the art that such a specific description is only a preferred embodiment, thereby not limiting the scope of the present invention. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims (8)

1. A compound represented by formula (1) or a pharmaceutically acceptable salt thereof:

   [Formula 1]

   
2. A pharmaceutical composition for preventing or treating aging-related diseases comprising a compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof:

   [Formula 1]

   
3. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof is (7S)-(+)-8,8-dimethyl-7- (3-phenyl-allyloxy) -7,8- Dihydro-6H-pyrano [3,2-g] chromen-2-one {(7S)-(+)-8,8-Dimethyl-7- (3-phenyl-allyloxy) -7,8-dihydro -6H-pyrano [3,2-g] chromen-2-one (SLC-D011)} pharmaceutical composition for the prevention or treatment of aging-related diseases.
4. The pharmaceutical composition for preventing or treating an aging-related disease according to claim 2, wherein the aging-related disease is premature ejaculation.
5. The pharmaceutical composition for preventing or treating aging-related diseases according to claim 4, wherein the premature ejaculation is selected from the group consisting of Werner syndrome and Hutchinson Gilford progria syndrome.
6. The pharmaceutical composition of claim 2, wherein the compound represented by Chemical Formula 1 and a pharmaceutically acceptable salt thereof inhibit the binding between progerin and lamin A.
7. A cosmetic composition for preventing or improving wrinkles comprising a compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof:

   [Formula 1]

   
8. The method according to claim 7, wherein the compound represented by the formula (1) and its pharmaceutically acceptable salts cosmetic composition for preventing or improving wrinkles, characterized in that to improve collagen production in keratinocytes and fibroblasts.

Images